4-乙酰氨基-N-(2'-氨基苯基)-苯甲酰胺
4-乙酰氨基-N-(2'-氨基苯基)-苯甲酰胺结构式
|
常用名 | 4-乙酰氨基-N-(2'-氨基苯基)-苯甲酰胺 | 英文名 | CI-994 |
|---|---|---|---|---|
| CAS号 | 112522-64-2 | 分子量 | 269.298 | |
| 密度 | 1.3±0.1 g/cm3 | 沸点 | 450.6±30.0 °C at 760 mmHg | |
| 分子式 | C15H15N3O2 | 熔点 | 242 °C(dec.) | |
| MSDS | 中文版 美版 | 闪点 | 226.3±24.6 °C | |
| 符号 |
GHS07 |
信号词 | Warning |
|
Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline).
Int. J. Cancer 62(5) , 636-42, (1995) The mechanism of action of the novel anti-cancer compound CI-994 was studied in C26 murine colon tumor and HCT-8 human colon adenocarcinoma cells. Treatment of either cell line resulted in the specific loss of a 16-kDa phosphoprotein in a time- and concentrat... |
|
|
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.
Cancer Invest. 22(6) , 886-96, (2004) To determine maximum tolerated dose of CI-994, a novel oral histone deacetylase inhibitor, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.Patients with advanced solid tumors who had received two or fewer prior chemothera... |
|
|
Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.
Clin. Cancer Res. 6(6) , 2474-81, (2000) Dose intensity, defined as dose administered per unit time, has emerged as a potentially important measurement of anticancer drug exposure and determinant of efficacy. There are several strategies for increasing dose intensity, one being a protracted daily do... |
|
|
Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue.
Arch. Toxicol. 73(3) , 168-74, (1999) CI-994 (acetyldinaline) is an investigative oral anticancer drug currently in clinical trials. To characterize the effects of CI-994 on lymphoid tissue, male rats were administered single oral doses at 0 (vehicle control), 10, 23, and 45 mg/kg and killed up t... |
|
|
In vivo development of an acetyldinaline resistant subline of the BN rat acute myelocytic leukemia (BNML).
Leukemia 7(8) , 1275-80, (1993) The cytostatic drug acetyldinaline [ACD, CI-994, 4-acetylamine-N-(2-aminophenyl)-benzamide] shows an extreme antileukemic effect in the Brown Norway (BN) rate model for acute myelocytic leukemia (BNML) with only minor toxicity for normal pluripotent hemopoiet... |
|
|
Latent hematopoietic stem cell toxicity associated with protracted drug administration.
Exp. Hematol. 29(3) , 286-94, (2001) The protracted administration of near-conventional daily doses of chemotherapeutic agents is a strategy to increase dose intensity and, potentially, efficacy as well. However, protracted therapy carries the risk of damage to stem cells in proliferative tissue... |
|
|
In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis.
Cancer Chemother. Pharmacol. 54(1) , 89-94, (2004) Acetyldinaline (CI-994) has shown preclinical efficacy in vitro and in vivo against solid tumor and leukemia cell lines. Since myelosuppression was the dose-limiting toxicity for acetyldinaline in preclinical and clinical studies, experiments were conducted t... |
|
|
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
Oncol. Res. 15(1) , 39-48, (2005) CI-994 (N-acetyldinaline) is a novel oral compound with a wide spectrum of antitumor activity in preclinical models, in vitro and in vivo. The mechanism of action may involve inhibition of histone deacetylation and cell cycle arrest. We studied the action of ... |
|
|
Incorporating targeted treatments into standard regimens: whither the role of established doses?
Cancer Invest. 22(6) , 954, (2004)
|
|
|
Leukemia cell lines resistant to cytosine arabinoside, cyclophosphamide or daunomycin are equally sensitive to the drug acetyldinaline as the parental cell line.
Leukemia 14(1) , 213-4, (2000)
|